



## **Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018**

July 24, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 24, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 7, 2018 at 8:00 A.M. ET to report its second quarter 2018 financial results and to discuss recent business updates.

The live webcast can be accessed on the investor page of Sage's website at [investor.sagerx.com](http://investor.sagerx.com). The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 5396188. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.

### **About Sage Therapeutics**

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA<sub>A</sub> and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180724005118/en/>

Source: Sage Therapeutics

Sage Therapeutics

**Investor Contact:**

Paul Cox, 617-299-8377

[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

or

**Media Contact:**

Maureen L. Suda, 585-355-1134

[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)